Danaher acquires Precision NanoSystems

By The Science Advisory Board staff writers

June 2, 2021 -- Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA (mRNA) vaccines.

Precision NanoSystems provides technology that supports the development and manufacturing of lipid nanoparticles to help deliver genetic medicines, including mRNA vaccines. The companies cited the rapid growth of the mRNA segment as one of the reasons behind the deal.

Precision NanoSystems will join Danaher's life sciences platform and will complement other Danaher subsidiaries including Cytiva and Pall. Precision NanoSystems will continue to develop a new manufacturing center in Vancouver as planned.

If you like this content, please share it with a colleague!

Related Reading

Precision NanoSystems launches T-cell kits for mRNA-lipid nanoparticles
Precision NanoSystems has launched its GenVoy-ILM T Cell Kit for messenger RNA (mRNA) to enable lipid nanoparticle-based ex vivo gene transfer.

Danaher announces chief executive transition
Danaher announced on May 6 that Executive Vice President Rainer Blair will succeed Thomas Joyce Jr. as president and CEO when Joyce retires on September...

GE BioPharma sale to Danaher is complete
The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

FTC greenlights $20B GE-Danaher deal
Following an agreement with the U.S. Federal Trade Commission (FTC), GE Healthcare Life Sciences is moving forward with the sale of its GE Biopharma business...